Of all the frightening phrases floating around the GLP-1 conversation, "stomach paralysis" might be the scariest, and it is the injury at the center of the lawsuits. So let's take the fear out of it by trading headlines for facts. Here is the single most important thing to understand, the piece most viral clips leave out: GLP-1 medications can slow your stomach's emptying as part of their intended effects. That is not automatically a malfunction. Gastroparesis is a specific, diagnosable condition that involves more serious or persistent symptoms. Knowing the difference is what separates panic from a plan.
What Is Gastroparesis, or "Stomach Paralysis"?
Gastroparesis is a medical condition characterized by delayed gastric emptying, where the stomach muscles do not contract normally to move food into the small intestine. This delay occurs in the absence of any physical blockage or obstruction in the digestive tract.
In plain language: in normal digestion, your stomach performs peristalsis, the rhythmic, wave-like muscle contractions that push food along into the small intestine. In gastroparesis, those contractions slow down or weaken, so food lingers in the stomach longer than expected. The word literally means "stomach paralysis," but that is a description of impaired movement, not a permanently frozen organ, an important distinction we will come back to.
Do GLP-1 Medications Cause Gastroparesis?
GLP-1 medications can slow gastric emptying as part of their intended effects, which may promote satiety and help regulate blood sugar. A claims-based study reported an association between GLP-1 use for weight loss and a higher risk of a gastroparesis diagnosis, while the absolute incidence remained low, at roughly 9 cases per 1,000 person-years for semaglutide compared with about 3 per 1,000 for the comparison medication. This observational result does not by itself prove that the medication caused every diagnosis.
This is where the mechanism and the condition get tangled together, so let's separate them. Slowing digestion is an intended effect of these drugs.[1] By keeping food in the stomach longer, GLP-1s can increase fullness and affect post-meal blood sugar. Gastroparesis is a more serious clinical condition involving delayed emptying and persistent symptoms. A widely cited 2023 study reported that GLP-1 users had roughly 3.7 times the risk of a gastroparesis diagnosis compared with people taking bupropion-naltrexone, a weight-loss medication unrelated to GLP-1s. The absolute numbers stayed low: about 9 gastroparesis diagnoses per 1,000 person-years among semaglutide users and 7 per 1,000 among liraglutide users, versus about 3 per 1,000 in the comparison group. Two caveats matter. The estimate came from a small number of events and carried a wide confidence interval, and the study identified gastroparesis from insurance billing codes or the use of a promotility medication rather than from a gastric emptying study.[2] People with diabetes or other conditions that affect digestive motility may need individualized assessment with their healthcare provider.
In the litigation sources reviewed for this article, gastroparesis was the most commonly alleged injury in the federal multidistrict litigation known as MDL-3094.[3] In that litigation, plaintiffs claim the manufacturers failed to adequately warn about the severity of this risk; the manufacturers deny these allegations and are actively defending their products. The cited proceedings were in early stages, with no verdicts or settlements reported at that time. For the full legal picture, see the GLP-1 lawsuits, explained. The other injury at the center of that litigation is vision loss, which we cover in GLP-1s and vision changes.
What Are the Warning Signs and Symptoms?
Normal GLP-1 side effects like mild nausea often occur during dose escalation and may settle as your body adjusts. Gastroparesis, by contrast, can involve persistent vomiting, sometimes of undigested food eaten hours earlier, along with severe bloating, abdominal pain, and early satiety that disrupts normal eating.
The clearest way to tell the difference is the pattern, duration, and severity of symptoms. Ordinary, manageable side effects tend to show up when you start or increase a dose and may settle as your body adjusts. The signs that warrant a closer look are different in kind: throwing up food you ate hours ago, being unable to eat or drink normally, or persistent pain and bloating that disrupt daily life. And some signs are true emergencies. If you experience severe dehydration, an inability to keep any liquids down, or vomiting blood, seek urgent medical care immediately, do not wait it out.
Can Symptoms Improve After GLP-1-Associated Gastroparesis?
Symptoms may improve after a medication is held or stopped under medical supervision, but the timeline varies. Persistent or severe symptoms can occur and require medical evaluation, sometimes with specialized gastroenterology care.
This is the reassuring part, and it is worth sitting with if the headlines have you rattled. Because medication-related slowing may lessen as the drug leaves the body, some people improve after a clinician adjusts or stops treatment. That does not mean the experience is trivial, and it does not guarantee a specific recovery timeline. Longer-lasting or unexplained symptoms need proper evaluation rather than a wait-and-see promise.
What Should You Do if You Are Concerned?
If you suspect gastroparesis, consult your prescribing healthcare provider, who may order a gastric emptying study to assess how quickly food leaves your stomach. Never alter or stop your medication on your own; those decisions belong with your provider under proper medical supervision.
A few concrete steps. First, the diagnosis itself is a medical one: a gastric emptying study tracks how quickly food leaves your stomach over several hours and is commonly used to evaluate delayed emptying, so this is not something to self-diagnose from a symptom checklist. Second, perioperative guidance has changed over time. In 2023, the American Society of Anesthesiologists advised considering holding GLP-1 medications before elective procedures, on the day of surgery for daily formulations and a week prior for weekly ones, because retained stomach contents can raise aspiration concerns.[4] A 2024 multi-society guidance from five organizations, including the ASA, moved toward individualized planning: it recommends shared decision-making among the patient, the prescribing clinician, and the anesthesia team, and notes that GLP-1 therapy may be continued before a procedure in patients without elevated risk factors for delayed gastric emptying.[5] Tell both your prescribing clinician and anesthesia team about your medication, symptoms, and dosing schedule rather than deciding alone.
Finally, on the nutrition side, and only as provider-guided support: if a doctor has confirmed that your digestion is slowed and you are struggling to eat enough, focusing on provider-approved, tolerable nutrient-dense liquids and supplements may help you maintain intake without overloading your stomach.[6] Choosing formats and timing that you can tolerate may matter more when eating is difficult, but no supplement is a treatment for gastroparesis. See supplement timing on a GLP-1 for the practical playbook. For food and fluid ideas, see what to eat on a GLP-1 and hydration on a GLP-1, and for practical discussion of oral products when digestion is slowed, what GLP-1s do to your digestion.
Frequently Asked Questions
How is "stomach paralysis" different from normal Ozempic nausea?
Normal nausea is often mild, tends to appear when you start or raise a dose, and may fade as your body adjusts. Gastroparesis can involve severe, persistent vomiting, sometimes of undigested food, along with intense bloating, pain, or difficulty maintaining normal intake.
Is gastroparesis from a GLP-1 permanent?
Not necessarily, but there is no single recovery timeline. Symptoms may improve after a clinician adjusts or stops the medication, while persistent symptoms need medical evaluation and sometimes specialist care. Do not stop or restart a GLP-1 without guidance.
What test is used to diagnose gastroparesis?
A gastric emptying study tracks how quickly food leaves your stomach over several hours and is commonly used to evaluate delayed emptying. It also helps clinicians assess other causes of similar symptoms, including a physical obstruction.
Should I stop taking my GLP-1 before surgery?
Do not make that decision on your own. Perioperative recommendations have evolved, and the plan can depend on the medication, dose, symptoms, procedure, and anesthesia team. Tell your prescribing clinician and anesthesia team that you take a GLP-1 so they can coordinate the safest plan.
Facts, Not Fear
Gastroparesis is real, serious, and worth understanding, but it is not the permanent horror the scariest clips suggest. The most useful things you can do are simple: know the difference between ordinary side effects and true warning signs, never adjust your medication on your own, and get a proper evaluation if something feels off. If a severely reduced appetite has you worried about opening up nutrient gaps, an HTMA test may provide complementary, non-diagnostic mineral-pattern context, but it is not a cellular baseline, a diagnostic test, or a substitute for your provider's evaluation. For the bigger foundation, start with the hidden nutrient gaps behind GLP-1 weight loss.
Rapid change on the outside. Steady support on the inside. Your minerals and nutrients, in your control.
References
- WEGOVY (semaglutide) injection, Prescribing Information. U.S. Food and Drug Administration; via DailyMed, U.S. National Library of Medicine. (Delayed gastric emptying as part of the drug's intended effects; gastrointestinal side effects.)
- Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023;330(18):1795-1797. doi:10.1001/jama.2023.19574 · PMID 37796527 · PMC10557026. (Claims-based cohort study; adjusted hazard ratio for gastroparesis 3.67, 95% CI 1.15-11.90, versus bupropion-naltrexone. Gastroparesis incidence per 1,000 person-years: 9.1 semaglutide, 7.3 liraglutide, 3.1 bupropion-naltrexone. Gastroparesis was identified by diagnostic code or promotility-agent use, not by gastric emptying study.)
- In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094, U.S. District Court, Eastern District of Pennsylvania. Official MDL-3094 court page. (Pretrial failure-to-warn allegations regarding gastroparesis severity; manufacturers deny the allegations and are defending.)
- American Society of Anesthesiologists Task Force on Preoperative Fasting. American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. June 29, 2023. asahq.org. (Advised considering holding GLP-1 agonists on the day of the procedure for daily dosing and one week prior for weekly dosing, citing delayed gastric emptying and aspiration risk.)
- Kindel TL, Wang AY, Wadhwa A, et al. Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surg Endosc. 2024;39(1):180-183. doi:10.1007/s00464-024-11263-2 · PMID 39370500 · PMC11666732. (Joint guidance from the American Gastroenterological Association, American Society for Metabolic and Bariatric Surgery, American Society of Anesthesiologists, International Society of Perioperative Care of Patients with Obesity, and Society of American Gastrointestinal and Endoscopic Surgeons. Recommends shared decision-making and individualized risk assessment; therapy may be continued preoperatively in patients without elevated risk.)
- Urbina J, et al. Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review. Clin Obes. 2026;16(1):e70070. doi:10.1111/cob.70070. (Reduced caloric intake and nutritional-gap context during therapy.)
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.